Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD

Lombard Odier Asset Management Switzerland SA raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,312 shares of the biopharmaceutical company’s stock after buying an additional 10,535 shares during the quarter. Lombard Odier Asset Management Switzerland SA’s holdings in Gilead Sciences were worth $5,911,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of the business. Activest Wealth Management raised its stake in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $27,000. Putney Financial Group LLC lifted its holdings in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new position in Gilead Sciences in the second quarter worth $30,000. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $126.54, for a total value of $1,265,400.00. Following the completion of the transaction, the chief executive officer directly owned 571,203 shares in the company, valued at approximately $72,280,027.62. This represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This represents a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 135,757 shares of company stock worth $16,616,127. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on GILD shares. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Citigroup upped their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $130.65.

Gilead Sciences Trading Down 0.0%

Shares of GILD opened at $121.19 on Tuesday. The stock has a market capitalization of $150.36 billion, a P/E ratio of 18.79, a PEG ratio of 0.67 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a fifty day simple moving average of $121.11 and a two-hundred day simple moving average of $115.44.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.